Lifelong Diabetes Self-Management Intervention

终身糖尿病自我管理干预

• 批准号: 7426448
• 负责人: TRICIA Shugin TANG
• 金额: $ 11.3万
• 依托单位: UNIVERSITY OF MICHIGAN AT ANN ARBOR
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-07-01 至 2010-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7426448
• 关键词: Accident and Emergency department; Adult; Affect; African American; Attention; Behavior; Biometry; Blood Glucose; Caring; Chronic Disease; Communities; Complications of Diabetes Mellitus; Data; Diabetes Mellitus; Doctor of Philosophy; Educational Intervention; Epidemiologic Studies; Expenditure; Faculty; Financial cost; Foundations; Health; Healthcare; Hospitalization; Intervention; Knowledge; Lead; Mentored Clinical Oncology Award; Mentored Clinical Scientist Award; Mentored Patient-Oriented Research Career Development Award; Mentors; Motivation; Non-Insulin-Dependent Diabetes Mellitus; Participant; Patient Education; Perceived quality of life; Population; Quality of life; Relative (related person); Research; Research Methodology; Research Personnel; Risk; Savings; Self Determination; Self Management; Time; Translations; United States; Visit; base; cancer prevention; career; concept; cost; disability; ethnic minority population; experience; follow-up; glucose monitor; glycemic control; health care service utilization; improved; patient oriented; programs; theories

DESCRIPTION (provided by applicant): Tricia S. Tang, Ph.D. is a junior faculty research investigator with research experience in cancer prevention and control among ethnic minorities. She is applying for a K23 award to support her decision to pursue a career in diabetes translation research among ethnic minority and other high-risk populations. Dr. Robert Anderson, an internationally known diabetes researcher, will serve as her mentor. In the Years 1-2, Dr. Tang will acquire a foundation in causes and treatment of diabetes, epidemiology, research methods, and biostatistics. In Years 1-5, she will conduct her proposed research described and utilize her data to prepare a R01/R18 submission. Diabetes is a chronic disease that incurs significant health, disability, and financial costs in the United States. African Americans are disproportionately affected by diabetes as they are two times more likely to have diabetes that their White counterparts and the suffer greater diabetes-related complications.1 Diabetes self-management interventions have shown to have only short-term positive effects on knowledge, blood glucose monitoring, dietary behavior, and glycemic control.2-5 This study will examine the efficacy of a community-based, self-management intervention (Lifelong Management) for urban adults (primarily African Americans) with type 2 diabetes that sustains, over the long-term diabetes-related health gains achieved by previous short-term patient education programs. Specific aims: Specific Aim 1: To examine the relative efficacy of 6-months of the Lifelong Management (LM) intervention compared to 6-months of an attention-control period in improving glycemic control and quality of life for urban African-American adults with type 2 diabetes. Specific Aim 2: To investigate whether gains achieved from the first 6-months of the LM intervention are sustained or enhanced over the long-term (18-months). Specific Aim 3: To examine whether glycemic control and quality of life decline during the year following the end of the LM intervention. Specific Aim 4: To examine the costs and potential health care savings of the LM intervention.

描述(由申请人提供)： 邓丽君博士是一名初级教研员，在少数民族癌症预防和控制方面有研究经验。她正在申请K23奖项，以支持她在少数民族和其他高危人群中从事糖尿病翻译研究的决定。国际知名的糖尿病研究人员罗伯特·安德森博士将担任她的导师。在1-2年内，唐博士将在糖尿病的病因和治疗、流行病学、研究方法和生物统计学方面获得基础。在第1-5年，她将进行她所描述的拟议研究，并利用她的数据准备R01/R18提交。 糖尿病是一种慢性疾病，在美国会导致巨大的健康、残疾和经济成本。非裔美国人受到糖尿病的影响不成比例，因为他们患糖尿病的可能性是白人和非裔美国人的两倍，而且他们患有糖尿病相关并发症的比例更高。1糖尿病自我管理干预已证明对知识、血糖监测、饮食行为和血糖控制只有短期的积极影响。2-5本研究将审查对患有2型糖尿病的城市成年人(主要是非裔美国人)实施以社区为基础的自我管理干预(终身管理)的有效性，这种干预持续了先前短期患者教育计划所取得的与糖尿病相关的长期健康收益。具体目标： 具体目标1：比较6个月的终生管理(LM)干预和6个月的注意力控制期在改善城市非裔美国人2型糖尿病成年人血糖控制和生活质量方面的相对有效性。 具体目标2：调查长期(18个月)长期干预前6个月取得的成果是持续的还是增强的。 具体目标3：检查在LM干预结束后的一年中，血糖控制和生活质量是否下降。 具体目标4：检查LM干预的成本和潜在的医疗节省。